Skip to main content
SpringerLink
Log in

Urothelial Tumors

  • Chapter
  • First Online:
Oncologic Imaging: Urology

  • 1374 Accesses

Abstract

Primary bladder neoplasms consist 2–6 % of all tumors, and bladder cancer is the fourth common malignancy [1]. Tumors can arise from the urothelium or other layers of the bladder wall. The bladder wall consists of four layers. The first layer is the uroepithelium. This consists of 3–7 layers of stratified flat cells. More superficial cells are flexible and change shape from cuboidal to flat with distension of the bladder. This is why we call it “transitional epithelium.” The second layer is the lamina propria. The third layer is the muscularis propria (detrusor muscle). The fourth layer is the adventitia. Bladder neoplasms arise from any of the four layers. They are classified into epithelial and nonepithelial tumors [1]. Epithelial tumors consist 95 % of bladder tumors. When epithelial tumor differentiates to normal urothelium, we call it urothelial. Other epithelial tumors include squamous cell carcinoma, adenocarcinoma, small cell/neuroendocrine carcinoma, carcinoid, and melanoma. These epithelial tumors occur at the surface of bladder lumen and usually show irregular, intraluminal mass.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Murphy WM GD, Perman EJ. Tumors of the kidney, bladder, and related urinary structures. Washington, DC: American Registry of Pathology; 2004. p. 394.

    Google Scholar 

  2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  3. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89:630–9.

    Article  CAS  PubMed  Google Scholar 

  4. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int. 2002;89:369–73.

    Article  CAS  PubMed  Google Scholar 

  5. Sadow CA, Silverman SG, O’Leary MP, Signorovitch JE. Bladder cancer detection with CT urography in an Academic Medical Center. Radiology. 2008;249:195–202.

    Article  PubMed  Google Scholar 

  6. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311–22.

    Article  PubMed  Google Scholar 

  7. Kawashima A, Vrtiska TJ, LeRoy AJ, Hartman RP, McCollough CH, King Jr BF. CT urography. Radiographics. 2004;24 Suppl 1:S35–54; discussion S55-38.

    Article  PubMed  Google Scholar 

  8. Ng CS. Radiologic diagnosis and staging of renal and bladder cancer. Semin Roentgenol. 2006;41:121–38.

    Article  PubMed  Google Scholar 

  9. Hall TMVA. Imaging of bladder cancer. Imaging. 2001;13:1–10.

    Article  Google Scholar 

  10. Tsampoulas C, Tsili AC, Giannakis D, Alamanos Y, Sofikitis N, Efremidis SC. 16-MDCT cystoscopy in the evaluation of neoplasms of the urinary bladder. AJR Am J Roentgenol. 2008;190:729–35.

    Article  PubMed  Google Scholar 

  11. Beer A, Saar B, Link TM, et al. Virtual endoscopy of the urinary tract from T(2)-weighted and gadolinium-enhanced T(1)-weighted MR urographic images. Rofo. 2001;173:997–1005.

    Article  CAS  PubMed  Google Scholar 

  12. Bernhardt TM, Rapp-Bernhardt U. Virtual cystoscopy of the bladder based on CT and MRI data. Abdom Imaging. 2001;26:325–32.

    Article  CAS  PubMed  Google Scholar 

  13. Verma S, Rajesh A, Prasad SR, et al. Urinary bladder cancer: role of MR imaging. Radiographics. 2012;32:371–87.

    Article  PubMed  Google Scholar 

  14. Jimenez RE, Gheiler E, Oskanian P, et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol. 2000;24:980–7.

    Article  CAS  PubMed  Google Scholar 

  15. Shinagare AB, Sadow CA, Sahni VA, Silverman SG. Urinary bladder: normal appearance and mimics of malignancy at CT urography. Cancer Imaging. 2011;11:100–8.

    Article  PubMed  PubMed Central  Google Scholar 

  16. McPartlin DS, Klausner AP, Nottingham CU, et al. Is cystoscopy indicated for incidentally identified bladder wall thickening? Can J Urol. 2013;20:6615–9.

    PubMed  Google Scholar 

  17. Wong-You-Cheong JJ, Woodward PJ, Manning MA, Sesterhenn IA. From the archives of the AFIP: neoplasms of the urinary bladder: radiologic-pathologic correlation. Radiographics. 2006;26:553–80.

    Article  PubMed  Google Scholar 

  18. Tekes A, Kamel I, Imam K, et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol. 2005;184:121–7.

    Article  PubMed  Google Scholar 

  19. Lawler LP. MR imaging of the bladder. Radiol Clin North Am. 2003;41:161–77.

    Article  PubMed  Google Scholar 

  20. Barentsz JO, Ruijs SH, Strijk SP. The role of MR imaging in carcinoma of the urinary bladder. AJR Am J Roentgenol. 1993;160:937–47.

    Article  CAS  PubMed  Google Scholar 

  21. Hood MN, Ho VB, Smirniotopoulos JG, Szumowski J. Chemical shift: the artifact and clinical tool revisited. Radiographics. 1999;19:357–71.

    Article  CAS  PubMed  Google Scholar 

  22. Semelka R. Abdominal-pelvic MRI. Hoboken: Wiley-Blackwell; 2010.

    Google Scholar 

  23. Neuerburg JM, Bohndorf K, Sohn M, Teufl F, Guenther RW, Daus HJ. Urinary bladder neoplasms: evaluation with contrast-enhanced MR imaging. Radiology. 1989;172:739–43.

    Article  CAS  PubMed  Google Scholar 

  24. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging. 2005;21:258–62.

    Article  PubMed  Google Scholar 

  25. Koh DM, Takahara T, Imai Y, Collins DJ. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci. 2007;6:211–24.

    Article  PubMed  Google Scholar 

  26. Abou-El-Ghar ME, El-Assmy A, Refaie HF, El-Diasty T. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology. 2009;251:415–21.

    Article  PubMed  Google Scholar 

  27. El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol. 2009;19:1575–81.

    Article  PubMed  Google Scholar 

  28. Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009;251:112–21.

    Article  PubMed  Google Scholar 

  29. Watanabe H, Kanematsu M, Kondo H, et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? AJR Am J Roentgenol. 2009;192:1361–6.

    Article  PubMed  Google Scholar 

  30. Beyersdorff D, Zhang J, Schoder H, Bochner B, Hricak H. Bladder cancer: can imaging change patient management? Curr Opin Urol. 2008;18:98–104.

    Article  PubMed  Google Scholar 

  31. Zhang J, Gerst S, Lefkowitz RA, Bach A. Imaging of bladder cancer. Radiol Clin North Am. 2007;45:183–205.

    Article  PubMed  Google Scholar 

  32. Scattoni V, Da Pozzo LF, Colombo R, et al. Dynamic gadolinium-enhanced magnetic resonance imaging in staging of superficial bladder cancer. J Urol. 1996;155:1594–9.

    Article  CAS  PubMed  Google Scholar 

  33. Hayashi N, Tochigi H, Shiraishi T, Takeda K, Kawamura J. A new staging criterion for bladder carcinoma using gadolinium-enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography. BJU Int. 2000;85:32–6.

    Article  CAS  PubMed  Google Scholar 

  34. Narumi Y, Kadota T, Inoue E, et al. Bladder tumors: staging with gadolinium-enhanced oblique MR imaging. Radiology. 1993;187:145–50.

    Article  CAS  PubMed  Google Scholar 

  35. Barentsz JO, Jager G, Mugler 3rd JP, et al. Staging urinary bladder cancer: value of T1-weighted three-dimensional magnetization prepared-rapid gradient-echo and two-dimensional spin-echo sequences. AJR Am J Roentgenol. 1995;164:109–15.

    Article  CAS  PubMed  Google Scholar 

  36. Edge SBBD, Compton CC, editors. AJCC cancer Staging manual. New York: Springer; 2010.

    Google Scholar 

  37. Wong-You-Cheong JJ, Wagner BJ, Davis Jr CJ. Transitional cell carcinoma of the urinary tract: radiologic-pathologic correlation. Radiographics. 1998;18:123–42; quiz 148.

    Article  CAS  PubMed  Google Scholar 

  38. Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol. 2003;47:155–69.

    Article  PubMed  Google Scholar 

  39. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52:594–601.

    Article  CAS  PubMed  Google Scholar 

  40. Lee TY, Ko SF, Wan YL, et al. Unusual imaging presentations in renal transitional cell carcinoma. Acta Radiol. 1997;38:1015–9.

    Article  CAS  PubMed  Google Scholar 

  41. Melamed MR, Reuter VE. Pathology and staging of urothelial tumors of the kidney and ureter. Urol Clin North Am. 1993;20:333–47.

    CAS  PubMed  Google Scholar 

  42. Urban BA, Buckley J, Soyer P, Scherrer A, Fishman EK. CT appearance of transitional cell carcinoma of the renal pelvis: part 1. Early-stage disease. AJR Am J Roentgenol. 1997;169:157–61.

    Article  CAS  PubMed  Google Scholar 

  43. Buckley JA, Urban BA, Soyer P, Scherrer A, Fishman EK. Transitional cell carcinoma of the renal pelvis: a retrospective look at CT staging with pathologic correlation. Radiology. 1996;201:194–8.

    Article  CAS  PubMed  Google Scholar 

  44. Keeley FX, Kulp DA, Bibbo M, McCue PA, Bagley DH. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. J Urol. 1997;157:33–7.

    Article  CAS  PubMed  Google Scholar 

  45. Herranz-Amo F, Diez-Cordero JM, Verdu-Tartajo F, Bueno-Chomon G, Leal-Hernandez F, Bielsa-Carrillo A. Need for intravenous urography in patients with primary transitional carcinoma of the bladder? Eur Urol. 1999;36:221–4.

    Article  CAS  PubMed  Google Scholar 

  46. Raman SP, Horton KM, Fishman EK. Transitional cell carcinoma of the upper urinary tract: optimizing image interpretation with 3D reconstructions. Abdom Imaging. 2012;37:1129–40.

    Article  PubMed  Google Scholar 

  47. Maheshwari E, O’Malley ME, Ghai S, Staunton M, Massey C. Split-bolus MDCT urography: upper tract opacification and performance for upper tract tumors in patients with hematuria. AJR Am J Roentgenol. 2010;194:453–8.

    Article  PubMed  Google Scholar 

  48. Chow LC, Kwan SW, Olcott EW, Sommer G. Split-bolus MDCT urography with synchronous nephrographic and excretory phase enhancement. AJR Am J Roentgenol. 2007;189:314–22.

    Article  PubMed  Google Scholar 

  49. Kekelidze M, Dwarkasing RS, Dijkshoorn ML, Sikorska K, Verhagen PC, Krestin GP. Kidney and urinary tract imaging: triple-bolus multidetector CT urography as a one-stop shop--protocol design, opacification, and image quality analysis. Radiology. 2010;255:508–16.

    Article  PubMed  Google Scholar 

  50. Caoili EM, Inampudi P, Cohan RH, Ellis JH. Optimization of multi-detector row CT urography: effect of compression, saline administration, and prolongation of acquisition delay. Radiology. 2005;235:116–23.

    Article  PubMed  Google Scholar 

  51. Johnson PT, Horton KM, Fishman EK. Optimizing detectability of renal pathology with MDCT: protocols, pearls, and pitfalls. AJR Am J Roentgenol. 2010;194:1001–12.

    Article  PubMed  Google Scholar 

  52. Browne RF, Meehan CP, Colville J, Power R, Torreggiani WC. Transitional cell carcinoma of the upper urinary tract: spectrum of imaging findings. Radiographics. 2005;25:1609–27.

    Article  PubMed  Google Scholar 

  53. Bechtold RB, Chen MY, Dyer RB, Zagoria RJ. CT of the ureteral wall. AJR Am J Roentgenol. 1998;170:1283–9.

    Article  CAS  PubMed  Google Scholar 

  54. Caoili EM, Cohan RH, Inampudi P, et al. MDCT urography of upper tract urothelial neoplasms. AJR Am J Roentgenol. 2005;184:1873–81.

    Article  PubMed  Google Scholar 

  55. Pretorius ES, Wickstrom ML, Siegelman ES. MR imaging of renal neoplasms. Magn Reson Imaging Clin N Am. 2000;8:813–36.

    CAS  PubMed  Google Scholar 

  56. Stein JP, Skinner EC, Boyd SD, Skinner DG. Squamous cell carcinoma of the bladder associated with cyclophosphamide therapy for Wegener’s granulomatosis: a report of 2 cases. J Urol. 1993;149:588–9.

    CAS  PubMed  Google Scholar 

  57. Serretta V, Pomara G, Piazza F, Gange E. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur Urol. 2000;37:85–9.

    Article  CAS  PubMed  Google Scholar 

  58. Dondalski M, White EM, Ghahremani GG, Patel SK. Carcinoma arising in urinary bladder diverticula: imaging findings in six patients. AJR Am J Roentgenol. 1993;161:817–20.

    Article  CAS  PubMed  Google Scholar 

  59. Tekes A, Kamel IR, Chan TY, Schoenberg MP, Bluemke DA. MR imaging features of non-transitional cell carcinoma of the urinary bladder with pathologic correlation. AJR Am J Roentgenol. 2003;180:779–84.

    Article  PubMed  Google Scholar 

  60. Wong JT, Wasserman NF, Padurean AM. Bladder squamous cell carcinoma. Radiographics. 2004;24:855–60.

    Article  PubMed  Google Scholar 

  61. Shokeir AA. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int. 2004;93:216–20.

    Article  CAS  PubMed  Google Scholar 

  62. Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. J Urol. 1984;131:1–8.

    CAS  PubMed  Google Scholar 

  63. Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases. Histopathology. 2000;36:32–40.

    Article  CAS  PubMed  Google Scholar 

  64. Hughes MJ, Fisher C, Sohaib SA. Imaging features of primary nonurachal adenocarcinoma of the bladder. AJR Am J Roentgenol. 2004;183:1397–401.

    Article  CAS  PubMed  Google Scholar 

  65. Brick SH, Friedman AC, Pollack HM, et al. Urachal carcinoma: CT findings. Radiology. 1988;169:377–81.

    Article  CAS  PubMed  Google Scholar 

  66. Yu JS, Kim KW, Lee HJ, Lee YJ, Yoon CS, Kim MJ. Urachal remnant diseases: spectrum of CT and US findings. Radiographics. 2001;21:451–61.

    Article  CAS  PubMed  Google Scholar 

  67. Ashley RA, Inman BA, Sebo TJ, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107:712–20.

    Article  PubMed  Google Scholar 

  68. Mohile SG, Schleicher L, Petrylak DP. Treatment of metastatic urachal carcinoma in an elderly woman. Nat Clin Pract Oncol. 2008;5:55–8.

    Article  PubMed  Google Scholar 

  69. Narumi Y, Sato T, Kuriyama K, et al. Vesical dome tumors: significance of extravesical extension on CT. Radiology. 1988;169:383–5.

    Article  CAS  PubMed  Google Scholar 

  70. Thali-Schwab CM, Woodward PJ, Wagner BJ. Computed tomographic appearance of urachal adenocarcinomas: review of 25 cases. Eur Radiol. 2005;15:79–84.

    Article  PubMed  Google Scholar 

  71. Rafal RB, Markisz JA. Urachal carcinoma: the role of magnetic resonance imaging. Urol Radiol. 1991;12:184–7.

    Article  CAS  PubMed  Google Scholar 

  72. Cheng L, Pan CX, Yang XJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004;101(5):957–62.

    Article  PubMed  Google Scholar 

  73. Sved P, Gomez P, Manoharan M, Civantos F, Soloway MS. Small cell carcinoma of the bladder. BJU Int. 2004;94:12–7.

    Article  PubMed  Google Scholar 

  74. Kim JC, Kim KH, Jung S. Small cell carcinoma of the urinary bladder: CT and MR imaging findings. Korean J Radiol. 2003;4:130–5.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Bates AW, Norton AJ, Baithun SI. Malignant lymphoma of the urinary bladder: a clinicopathological study of 11 cases. J Clin Pathol. 2000;53:458–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Dighe MK, Bhargava P, Wright J. Urinary bladder masses: techniques, imaging spectrum, and staging. J Comput Assist Tomogr. 2011;35:411–24.

    Article  PubMed  Google Scholar 

  77. Maya MM, Slywotzky C. Urinary bladder leiomyoma: magnetic resonance imaging findings. Urol Radiol. 1992;14:197–9.

    Article  CAS  PubMed  Google Scholar 

  78. Metzdorf MM, Schmidt JD. Urinary bladder leiomyoma associated with pulmonary lymphangioleiomyomatosis. Urology. 2008;71:755.e3–4.

    Article  Google Scholar 

  79. Cornella JL, Larson TR, Lee RA, Magrina JF, Kammerer-Doak D. Leiomyoma of the female urethra and bladder: report of twenty-three patients and review of the literature. Am J Obstet Gynecol. 1997;176:1278–85.

    Article  CAS  PubMed  Google Scholar 

  80. Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC); 2004.

    Google Scholar 

  81. Hodges KB, Lopez-Beltran A, Davidson DD, et al. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol. 2010;41(2):155–62.

    Article  PubMed  Google Scholar 

  82. Lopez-Beltran A, Montironi R, Vidal A, et al. Urothelial dysplasia of the bladder: diagnostic features and clinical significance. Anal Quant Cytopathol Histpathol. 2013;35(3):121–9.

    PubMed  Google Scholar 

  83. McKenney JK, Gomez JA, Desai S, et al. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001;25(3):356–62.

    Article  CAS  PubMed  Google Scholar 

  84. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25(8):1074–8.

    Article  CAS  PubMed  Google Scholar 

  85. Billis A, Schenka AA, Ramos CC, et al. Squamous and/or glandular differentiation in urothelial carcinoma: prevalence and significance in transurethral resections of the bladder. Int Urol Nephrol. 2001;33(4):631–3.

    Article  CAS  PubMed  Google Scholar 

  86. Lee YJ, Moon KC, Jeong CW, et al. Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma. PLoS One. 2014;9(9):e107027.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Lopez-Beltran A, Requena MJ, Alvarez-Kindelan J, et al. Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. J Clin Pathol. 2007;60(3):332–5.

    Article  PubMed  Google Scholar 

  88. Wasco MJ, Daignault S, Zhang Y, et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology. 2007;70(1):69–74.

    Article  PubMed  Google Scholar 

  89. Dhall D, Al-Ahmadie H, Olgac S. Nested variant of urothelial carcinoma. Arch Pathol Lab Med. 2007;131(11):1725–7.

    PubMed  Google Scholar 

  90. Ricardo-Gonzalez RR, Nguyen M, Gokden N, et al. Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread. J Urol. 2012;187(3):852–5.

    Article  PubMed  Google Scholar 

  91. Kwon GY, Ro JY. Micropapillary variant of urothelial carcinoma. Adv Urol. 2011;2011:217153.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Samaratunga H, Khoo K. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology. 2004;45(1):55–64.

    Article  CAS  PubMed  Google Scholar 

  93. Cheng L, Zhang S, Alexander R, et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol. 2011;35(5):e34–46.

    Article  PubMed  Google Scholar 

  94. Sharfi AR, el Sir S, Beleil O. Squamous cell carcinoma of the urinary bladder. Br J Urol. 1992;69(4):369–71.

    Article  CAS  PubMed  Google Scholar 

  95. Gopalan A, Sharp DS, Fine SW, et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol. 2009;33(5):659–68.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Velcheti V, Govindan R. Metastatic cancer involving bladder: a review. Can J Urol. 2007;14(1):3443–8.

    PubMed  Google Scholar 

  97. Chen YB, Epstein JI. Primary carcinoid tumors of the urinary bladder and prostatic urethra: a clinicopathologic study of 6 cases. Am J Surg Pathol. 2011;35(3):442–6.

    CAS  PubMed  Google Scholar 

  98. Martignoni G, Eble JN. Carcinoid tumors of the urinary bladder. Immunohistochemical study of 2 cases and review of the literature. Arch Pathol Lab Med. 2003;127(1):e22–4.

    PubMed  Google Scholar 

  99. Yang CH, Krzyzaniak K, Brown WJ, et al. Primary carcinoid tumor of urinary bladder. Urology. 1985;26(6):594–7.

    Article  CAS  PubMed  Google Scholar 

  100. Zhao X, Flynn EA. Small cell carcinoma of the urinary bladder: a rare, aggressive neuroendocrine malignancy. Arch Pathol Lab Med. 2012;136(11):1451–9.

    Article  PubMed  Google Scholar 

  101. Kempton CL, Kurtin PJ, Inwards DJ, et al. Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma. Am J Surg Pathol. 1997;21(11):1324–33.

    Article  CAS  PubMed  Google Scholar 

  102. Wiesner C, Jäger W, Thüroff JW. Surgery illustrated – surgical atlas. BJU Int. 2010;105:1610–21.

    Article  PubMed  Google Scholar 

  103. Althausen AF, Prout Jr GR, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 1976;116:575–80.

    CAS  PubMed  Google Scholar 

  104. Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992;19:499–508.

    CAS  PubMed  Google Scholar 

  105. Sweeney P, Kursh ED, Resnick MI. Partial cystectomy. Urol Clin North Am. 1992;19:701–11.

    CAS  PubMed  Google Scholar 

  106. Challacombe BJ, Bochner BH, Dasgupta P, Gill I, Guru K, Herr H, Mottrie A, Pruthi R, Redorta JP, Wiklund P. The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol. 2011;60:767–75.

    Article  PubMed  Google Scholar 

  107. Schilling D, Horstmann M, Nagele U, Sievert KD, Stenzl A. Cystectomy in women. BJU Int. 2008;102:1289–95.

    Article  PubMed  Google Scholar 

  108. Hautmann RE. The ileal neobladder to the female urethra. Urol Clin North Am. 1997;24:827–35.

    Article  CAS  PubMed  Google Scholar 

  109. Benson MC, Olsson CA. Urinary diversion. Urol Clin North Am. 1992;19:779–95.

    CAS  PubMed  Google Scholar 

  110. Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778–92.

    Article  PubMed  Google Scholar 

  111. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  112. Abouassaly R, Alibhai SM, Shah N, Timilshina N, Fleshner N, Finelli A. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology. 2010;76:895–901.

    Article  PubMed  Google Scholar 

  113. Jeldres C, Sun M, Isbarn H, Lughezzani G, Budäus L, Alasker A, Shariat SF, Lattouf JB, Widmer H, Pharand D, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. Urology. 2010;75:315–20.

    Article  PubMed  Google Scholar 

  114. Grasso M, Fishman AI, Cohen J, Alexander B. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int. 2012;110:1618–26.

    Article  PubMed  Google Scholar 

  115. Rouprêt M, Babjuk M, Compérat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63:1059–71.

    Article  PubMed  Google Scholar 

  116. Zigeuner RE, Hutterer G, Chromecki T, et al. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int. 2006;98:1181–6.

    Article  PubMed  Google Scholar 

  117. Ristau BT, Tomaszewski JJ, Ost MC. Upper tract urothelial carcinoma: current treatment and outcomes. Urology. 2012;79:749–56.

    Article  PubMed  Google Scholar 

  118. Zargar H, Krishnan J, Autorino R, Akca O, Brandao LF, Laydner H, Samarasekera D, Ko O, Haber GP, Kaouk JH, Stein RJ. Robotic nephroureterectomy: a simplified approach requiring no patient repositioning or robot redocking. Eur Urol. 2014;66:769–77.

    Article  PubMed  Google Scholar 

  119. Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012;61:818–25.

    Article  PubMed  Google Scholar 

  120. Kondo T, Hashimoto Y, Kobayashi H, et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. Int J Urol. 2010;17:848–54.

    Article  PubMed  Google Scholar 

  121. Rojas CP, Castle SM, Llanos CA, Santos Cortes JA, Bird V, Rodriguez S, Reis IM, Zhao W, Gomez-Fernandez C, Leveillee RJ, Jorda M. Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urol Oncol. 2013;31:1696–700.

    Article  PubMed  Google Scholar 

  122. Raman JD, Scherr DS. Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol. 2007;4:432–43.

    Article  PubMed  Google Scholar 

  123. Park BH, Jeon SS. Endoscopic management of upper urinary tract urothelial carcinoma. Korean J Urol. 2013;54:426–32.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Bagley DH, Grasso 3rd M. Ureteroscopic laser treatment of upper urinary tract neoplasms. World J Urol. 2010;28:143–9.

    Article  PubMed  Google Scholar 

  125. Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer. 2009;45:3291–7.

    Article  PubMed  Google Scholar 

  126. Jeldres C, Lughezzani G, Sun M, Isbarn H, Shariat SF, Budaus L, Lattouf JB, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol. 2010;183:1324–9.

    Article  PubMed  Google Scholar 

  127. Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–73.

    PubMed  Google Scholar 

  128. Calhoun A, Pohar K. Guideline-based management of muscle-invasive bladder cancer: NCCN, ICUD, and EAU. In: Konety BR, Chang SS, editors. Management of bladder cancer. New York: Springer; 2015. p. 457–63.

    Google Scholar 

  129. Sternberg C, Yagoda A, Scher H, Watson R, Ahmed T, Weiselberg L, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985;133:403–7.

    CAS  PubMed  Google Scholar 

  130. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050–5.

    CAS  PubMed  Google Scholar 

  131. Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, et al. Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997;80:1966–72.

    Article  CAS  PubMed  Google Scholar 

  132. von der Maase H, Hansen S, Roberts J, Dogliotti L, Oliver T, Moore M, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–77.

    PubMed  Google Scholar 

  133. Sternberg CN, de Mulder PHM, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638–46.

    CAS  PubMed  Google Scholar 

  134. Peters GJ, Bergman AM, Ruiz vHV, Veerman G, Kuiper CM, Braakhuis B. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 1995;22:72–9.

    CAS  PubMed  Google Scholar 

  135. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921–7.

    CAS  PubMed  Google Scholar 

  136. Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876–81.

    CAS  PubMed  Google Scholar 

  137. Von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol. 1999;10:1461–5.

    Article  PubMed  Google Scholar 

  138. Carteni G, Dogliotti L, Crucitta E, Martoni A, Siena S, Onat H, et al. Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). Proc Am Soc Clin Oncol. 2003;22:384.

    Google Scholar 

  139. Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol. 2012;61:1229–38.

    Article  PubMed  Google Scholar 

  140. Nishimura K, Fujiyama C, Nakashima K, Satoh Y, Tokuda Y, Uozumi J. The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall. Int Urol Nephrol. 2009;41:869–75.

    Article  CAS  PubMed  Google Scholar 

  141. Sternberg CN, Pansadoro V, Calabro F, Schnetzer S, Giannarelli D, Emiliozzi P, et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer. 2003;97:1644–52.

    Article  PubMed  Google Scholar 

  142. Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, et al; Nordic Urothelial Cancer Group. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004;45:297–303.

    Google Scholar 

  143. Collaboration ABCM-a. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202.

    Article  Google Scholar 

  144. Vale C, Collaboration ABCM-a. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927–34.

    Article  CAS  Google Scholar 

  145. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004;171:561–9.

    Article  CAS  PubMed  Google Scholar 

  146. International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171.

    Article  PubMed Central  Google Scholar 

  147. Collaboration ABCM-a. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48:189.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Kanwon National University Hospital, Seoul National University College of Medicine, Gangwon-do, Seoul, Republic of Korea

    Hyuck Jae Choi

  2. Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

    Kyung Chul Moon

  3. Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

    Jin Ho Kim

  4. Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

    Ja Hyeon Ku

Authors
  1. Hyuck Jae Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyung Chul Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin Ho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ja Hyeon Ku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hyuck Jae Choi .

Editor information

Editors and Affiliations

  1. Department of Radiology, Seoul National University Hospital, Seoul, Korea (Republic of)

    Seung Hyup Kim

  2. Department of Radiology, Seoul National University Hospital, Seoul, Korea (Republic of)

    Jeong Yeon Cho

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Choi, H.J., Moon, K.C., Kim, J.H., Ku, J.H. (2017). Urothelial Tumors. In: Kim, S., Cho, J. (eds) Oncologic Imaging: Urology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45218-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45218-9_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45217-2

  • Online ISBN: 978-3-662-45218-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation